Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2015-04-21 Regulatory Filings
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
FORM 6-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, RedHill Biopharma Ltd., submitted to the SEC. It includes a press release announcing a conference call for first quarter 2015 financial results. The document is short (2293 characters) and primarily serves as an announcement of an upcoming earnings call, not the call transcript itself or detailed financial results. It does not contain actual financial statements or detailed analysis. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings and announcements that do not fit other specific categories.
2015-04-21 English
FORM 6-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing submitted by a foreign private issuer, RedHill Biopharma Ltd., pursuant to SEC rules. It is dated April 2015 and includes a press release about a patent allowance. The document is short (2323 characters) and primarily serves as a regulatory update rather than a full financial report or detailed filing. It does not contain financial statements or detailed management discussion. Form 6-K filings are periodic reports for foreign private issuers to disclose material information and are generally classified under Regulatory Filings (RNS) as they do not fit other specific categories like Annual Report or Interim Report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2015-04-16 English
FORM 6-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by RedHill Biopharma Ltd., which is a report of a foreign private issuer pursuant to SEC rules. It includes a press release about an acquisition of a Phase II oral small molecule SK2 inhibitor. The document is short (2302 characters) and primarily serves as an announcement of a corporate event (acquisition) rather than a detailed financial report or earnings release. Form 6-K filings typically serve as regulatory filings for foreign issuers to disclose material information. There is no detailed financial data, earnings information, or management discussion. Therefore, the document fits best under Regulatory Filings (RNS) as a general regulatory announcement and press release filing.
2015-03-31 English
FORM 6-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by RedHill Biopharma Ltd. dated March 2015. It is a report of a foreign private issuer pursuant to SEC rules, containing a press release about a presentation at a forum. The document is short (2292 characters) and primarily announces an event (presentation) rather than providing detailed financial data or comprehensive reports. It does not contain financial statements, management discussion, or audit information. It is not an earnings release or annual/interim report. The document is essentially a regulatory announcement filing with a press release attached. According to the rules, such filings that do not fit other categories and are brief announcements fall under Regulatory Filings (RNS).
2015-03-23 English
FORM 6-K
Regulatory Filings Classification · 100% confidence The document is a Form 6-K filed by a foreign private issuer, Redhill Biopharma Ltd., pursuant to the Securities Exchange Act of 1934. It includes an exhibit description of a Master Service Agreement and references incorporation by way of reference into other registration statements. The document length is short (2097 characters) and primarily serves as a regulatory filing to disclose material agreements and updates to the SEC. It does not contain financial statements, earnings data, or detailed management discussion. It is not an annual or interim report, nor an earnings release or presentation. The document fits the definition of a Regulatory Filing (RNS) as a general regulatory announcement and compliance document that does not fit into other specific categories.
2015-03-13 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about a presentation at an online investor conference. The document is short (1864 characters) and primarily serves as an announcement of an event rather than containing detailed financial data or a full report. It does not contain financial statements or substantive financial analysis. According to the rules, such filings that are announcements or press releases attached to a Form 6-K are best classified as Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2015-03-03 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.